Vera Therapeutics' TRUTAKNA Shows Long-Term Kidney Disease Progression Benefits in IgA Nephropathy
Event summary
- TRUTAKNA met all prespecified endpoints in the ORIGIN 3 trial, showing stabilization of eGFR and prevention of kidney disease progression through two years.
- The treatment demonstrated a 76% risk reduction in composite kidney disease progression events compared to placebo.
- Vera Therapeutics plans to submit a supplemental BLA to the FDA for full approval in Q4 2026.
- The company has generated over 350 patient start forms in the first ten weeks of commercial launch.
- TRUTAKNA was well tolerated with a favorable safety profile generally comparable to placebo.
The big picture
Vera Therapeutics' positive ORIGIN 3 trial results for TRUTAKNA mark a significant milestone in the treatment of IgA nephropathy, a progressive kidney disease with limited therapeutic options. The data supports the potential for TRUTAKNA to become a disease-modifying therapy, addressing a critical unmet need in nephrology. The upcoming regulatory submission and strong commercial launch momentum position Vera Therapeutics for potential market leadership in this space.
What we're watching
- Regulatory Approval
- Whether the FDA will grant full approval for TRUTAKNA in 2027 based on the supplemental BLA submission.
- Commercial Momentum
- The pace at which Vera Therapeutics can sustain and grow the commercial launch momentum of TRUTAKNA.
- Long-Term Efficacy
- How the long-term efficacy and safety data of TRUTAKNA will impact its market position in IgA nephropathy treatment.
Related topics